BioCentury | Nov 6, 2014
Distillery Techniques

Technology: Drug delivery

...published online Sept. 29, 2014; doi:10.1002/jps.24193 Contact: Fakhrul Ahsan, Texas Tech University Health Sciences Center, Amarillo...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Cancer

...published online Oct. 1, 2014; doi:10.1038/ncomms6086 Contact: Ruiwen Zhang, Texas Tech University Health Sciences Center, Amarillo...
BioCentury | Jul 2, 2012
Clinical News

Oral interferon-alpha lozenges: Phase II data

...Vita's CytoPharm Inc. subsidiary and Amarillo reported data from a double-blind, Taiwanese Phase II trial in...
...rights for all indications in other Asian countries (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Jul 2, 2012
Company News

Amarillo infectious, inflammation news

...to distribute in the U.S. Amarillo plans to have the center fully operational this quarter. Amarillo's...
...countries (see BioCentury, March 9, 2009, Oct. 12, 2009 & Oct. 24, 2011). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Feb 27, 2012
Company News

Amarillo management update

...Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas Business: Autoimmune, Infectious, Inflammation Hired: Stephen Chen, a director, as...
BioCentury | Oct 24, 2011
Clinical News

Oral interferon-alpha lozenges: Phase II start

...This quarter, Vita's CytoPharm Inc. subsidiary and Amarillo will begin a double-blind, placebo-controlled, Taiwanese Phase II...
...days vs. Tamiflu alone in about 60 patients. Intas has Indian and Nepalese rights to Amarillo's...
...NEU1 ; SIAL1 ) inhibitor from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Mar 7, 2011
Financial News

Amarillo proposes follow-on

...Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas Business: Autoimmune, Infectious, Inflammation Date announced: 3/1/11 Type: Follow-on To...
BioCentury | Dec 20, 2010
Clinical News

Oral interferon-alpha lozenges: Completed Phase II enrollment

...500 and 1,500 units/day oral interferon-alpha lozenges for 24 weeks. CytoPharm has rights to develop Amarillo's...
...all indications in the rest of the world (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | May 3, 2010
Clinical News

Oral interferon-alpha lozenges: Final Phase II data

...significantly reduce the incidence of moderate to severe fever and head congestion vs. placebo (p<0.05). Amarillo...
...43% vs. 71%, p=0.01) (see BioCentury, Feb. 15). Intas has Indian and Nepalese rights to Amarillo's...
...countries (see BioCentury, March 9, 2009). CSL Ltd. (ASX:CSL, Melbourne, Australia) markets Fluvax. Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Mar 15, 2010
Clinical News

Oral interferon-alpha lozenges: Phase III start

...in up to 520 patients with influenza-like symptoms. Intas has Indian and Nepalese rights to Amarillo's...
...rights for all indications in other Asian countries (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
Items per page:
1 - 10 of 90
BioCentury | Nov 6, 2014
Distillery Techniques

Technology: Drug delivery

...published online Sept. 29, 2014; doi:10.1002/jps.24193 Contact: Fakhrul Ahsan, Texas Tech University Health Sciences Center, Amarillo...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Cancer

...published online Oct. 1, 2014; doi:10.1038/ncomms6086 Contact: Ruiwen Zhang, Texas Tech University Health Sciences Center, Amarillo...
BioCentury | Jul 2, 2012
Clinical News

Oral interferon-alpha lozenges: Phase II data

...Vita's CytoPharm Inc. subsidiary and Amarillo reported data from a double-blind, Taiwanese Phase II trial in...
...rights for all indications in other Asian countries (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Jul 2, 2012
Company News

Amarillo infectious, inflammation news

...to distribute in the U.S. Amarillo plans to have the center fully operational this quarter. Amarillo's...
...countries (see BioCentury, March 9, 2009, Oct. 12, 2009 & Oct. 24, 2011). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Feb 27, 2012
Company News

Amarillo management update

...Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas Business: Autoimmune, Infectious, Inflammation Hired: Stephen Chen, a director, as...
BioCentury | Oct 24, 2011
Clinical News

Oral interferon-alpha lozenges: Phase II start

...This quarter, Vita's CytoPharm Inc. subsidiary and Amarillo will begin a double-blind, placebo-controlled, Taiwanese Phase II...
...days vs. Tamiflu alone in about 60 patients. Intas has Indian and Nepalese rights to Amarillo's...
...NEU1 ; SIAL1 ) inhibitor from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Mar 7, 2011
Financial News

Amarillo proposes follow-on

...Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas Business: Autoimmune, Infectious, Inflammation Date announced: 3/1/11 Type: Follow-on To...
BioCentury | Dec 20, 2010
Clinical News

Oral interferon-alpha lozenges: Completed Phase II enrollment

...500 and 1,500 units/day oral interferon-alpha lozenges for 24 weeks. CytoPharm has rights to develop Amarillo's...
...all indications in the rest of the world (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | May 3, 2010
Clinical News

Oral interferon-alpha lozenges: Final Phase II data

...significantly reduce the incidence of moderate to severe fever and head congestion vs. placebo (p<0.05). Amarillo...
...43% vs. 71%, p=0.01) (see BioCentury, Feb. 15). Intas has Indian and Nepalese rights to Amarillo's...
...countries (see BioCentury, March 9, 2009). CSL Ltd. (ASX:CSL, Melbourne, Australia) markets Fluvax. Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
BioCentury | Mar 15, 2010
Clinical News

Oral interferon-alpha lozenges: Phase III start

...in up to 520 patients with influenza-like symptoms. Intas has Indian and Nepalese rights to Amarillo's...
...rights for all indications in other Asian countries (see BioCentury, March 9, 2009). Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo...
Items per page:
1 - 10 of 90